TITLE:
Dantrolene in the Treatment of Refractory Hyperthermic Conditions in Critical Care: A Multicenter Retrospective Study
AUTHORS:
Shonali C. Pawar, Henry Rosenberg, Robert Adamson, Jennifer A. LaRosa, Ronald Chamberlain
KEYWORDS:
Dantrolene, Malignant Hyperthermia, Neuroleptic Malignant Syndrome, Sepsis
JOURNAL NAME:
Open Journal of Anesthesiology,
Vol.5 No.4,
April
15,
2015
ABSTRACT: Purpose: To examine the use of intravenous dantrolene in hospitalized patients. Materials and Methods: Medical Records of patients treated with intravenous dantrolene between 2007 and 2012 at 6 teaching hospitals were reviewed. Temperature, muscle rigidity, creatine kinase levels, and mortality were assessed in association with dantrolene use. Results: Twenty-five patients received intravenous dantrolene, 9 patients with neuroleptic malignant syndrome (NMS), 8 with hyperthermia due to sepsis, 4 with NMS and sepsis, 2 for malignant hyperthermia (MH), and 2 with hypermetabolic syndrome associated with juvenile diabetic ketoacidosis. Dantrolene was administered as a bolus of 1 - 3 mg/kg. Core temperature decreased after dantrolene administration in all groups but significant only for MH, NMS cases (Pre 102.3 ± 0.9°F vs. Post 99.5 ± 0.9°F; p Conclusion: Dantrolene was associated with reductions in temperature and rigidity in hyperthermia of diverse origins in patients admitted to Intensive care settings.